GlassScriptPhysician profile
Brittany N Lambert
NPI 1417448424
$3,564.81
in general payments reported to CMS, 2019-2025
29 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.00 · 2022: $986 · 2023: $972 · 2024: $852 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $679.29 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $581.87 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $495.29 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $108.08 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.63 | 2022-2024 | Xifaxan |
| Amgen INC. | $95.85 | 2022-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $83.23 | 2022 | |
| Esperion Therapeutics, INC. | $81.11 | 2022-2024 | Nexletol |
| Pfizer INC. | $75.94 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $55.58 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.57 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $33.82 | 2023-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $29.88 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $29.62 | 2022-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $29.20 | 2022-2023 | Freestyle Libre 3 |
| Noven Therapeutics, LLC | $28.38 | 2024 | Xelstrym |
| Organon LLC | $25.50 | 2025 | Nexplanon |
| Nevro Corp. | $24.18 | 2024 | Senza |
| Idorsia Pharmaceuticals US INC | $23.82 | 2023 | Quviviq |
| Gilead Sciences, INC. | $22.92 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.99 | 2025 | Voquezna |
| Si-Bone, INC. | $19.32 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.06 | 2024 | Keveyis |
| Jazz Pharmaceuticals INC. | $17.19 | 2022 | |
| Valencia Technologies Corporation | $15.94 | 2025 | Ecoin Device Kit |
| Amneal Pharmaceuticals LLC | $13.86 | 2025 | Unithroid |
| Amarin Pharma, INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.